Description

Encorat (valproic acid) Coated Tablets with Prolonged Release 500 mg. №30

Ingredients:

Each coated tablet contains 500 mg of valproic acid.

Dosage:

The recommended dosage is determined by a healthcare provider based on individual needs. It is typically taken once or twice daily with food to reduce stomach upset.

Indications:

Encorat tablets are indicated for the treatment of epilepsy, bipolar disorder, and migraine headaches. They work by restoring the balance of certain natural substances in the brain.

Contraindications:

Do not use Encorat if you have liver disease, a urea cycle disorder, or a genetic mitochondrial disorder. It is important to inform your doctor about all medical conditions before starting this medication.

Directions:

Swallow the tablets whole, do not crush or chew them. Follow the instructions provided by your healthcare provider for the best results.

Scientific Evidence:

Studies have shown that valproic acid, the active ingredient in Encorat, is effective in managing seizures and stabilizing mood in patients with bipolar disorder. Research published in the Journal of Clinical Psychopharmacology demonstrated the efficacy of valproic acid in reducing the frequency of migraine attacks.

Additional Information:

Encorat tablets with prolonged release provide a steady level of medication in the blood, reducing the number of doses needed per day. It is important to attend regular check-ups with your healthcare provider to monitor the effects of the medication.

Valproic acid, the active ingredient in Encorat, exerts its pharmacological effects by increasing the levels of gamma-aminobutyric acid (GABA) in the brain, which has inhibitory effects on neurotransmission. This action helps to prevent abnormal electrical activity in the brain, reducing the occurrence of seizures in epilepsy patients and stabilizing mood in individuals with bipolar disorder.

Clinical trials have shown that Encorat with prolonged release formulation offers improved patient compliance and convenience compared to immediate-release formulations. A study published in the Journal of Neurology found that patients taking prolonged-release valproic acid experienced fewer side effects and better tolerability, leading to improved treatment adherence.